As M&A Deals Rise, Can Biotech Pharma Break Loose?
Etftrendsยท2025-09-19 21:09
Group 1 - The biopharma sector experienced a sluggish M&A activity in 2024, but the environment is expected to improve for deals in the remainder of 2025 [1] - The overall industry sentiment is shifting, indicating a potential increase in M&A transactions as market conditions become more favorable [1] - Factors contributing to the improved M&A landscape include evolving market dynamics and strategic interests among companies [1]